Aliases & Classifications for Ischemia

Aliases & Descriptions for Ischemia:

Name: Ischemia 12 52 42 14 69
Acute Coronary Syndrome 42 69

Classifications:



External Ids:

Disease Ontology 12 DOID:326
NCIt 47 C34738
SNOMED-CT 64 52674009
UMLS 69 C0022116

Summaries for Ischemia

Disease Ontology : 12 A vascular disease that is characterized by a restriction in blood supply to tissues.

MalaCards based summary : Ischemia, also known as acute coronary syndrome, is related to myocardial infarction and bronchiolitis obliterans, and has symptoms including anoxemia, polydipsia and muscle weakness. An important gene associated with Ischemia is EGR1 (Early Growth Response 1), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and Allograft rejection. The drugs Colchicine and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and heart, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and behavior/neurological

Wikipedia : 71 Ischemia or ischaemia is a restriction in blood supply to tissues, causing a shortage of oxygen and... more...

Related Diseases for Ischemia

Diseases related to Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 508)
id Related Disease Score Top Affiliating Genes
1 myocardial infarction 31.8 CASP3 CXCL12 EDN1 HIF1A MPO NOS3
2 bronchiolitis obliterans 29.5 ADORA1 EDN1 NOS2
3 acute posterior multifocal placoid pigment epitheliopathy 29.4 EDN1 HIF1A NOS3 VEGFA
4 viral hepatitis 29.2 CAV1 EDN1 NOS2 NOS3
5 transient cerebral ischemia 12.2
6 brain ischemia 12.2
7 critical limb ischemia 12.2
8 retinal ischemia 12.0
9 limb ischemia 12.0
10 mesenteric artery ischemia 12.0
11 chronic myocardial ischemia 12.0
12 coronary artery disease 11.2
13 vascular disease 11.2
14 cerebral hypoxia 11.2
15 hypoxia 11.1
16 ischemic heart disease 11.1
17 vertebrobasilar insufficiency 11.1
18 myocardial stunning 11.0
19 intermittent claudication 11.0
20 temporal arteritis 10.9
21 calciphylaxis 10.9
22 central retinal vein occlusion 10.9
23 spermatic cord torsion 10.9
24 cerebral atherosclerosis 10.9
25 fibrocartilaginous embolism 10.9
26 chronic intestinal vascular insufficiency 10.9
27 cerebritis 10.8
28 arterial calcification, generalized, of infancy, 1 10.7
29 arterial calcification, generalized, of infancy, 2 10.7
30 nonarteritic anterior ischemic optic neuropathy 10.7
31 sturge-weber syndrome, somatic, mosaic 10.7
32 mini stroke 10.7
33 legg-calve-perthes disease 10.7
34 acute vascular insufficiency of intestine 10.7
35 microvascular complications of diabetes 1 10.6
36 microvascular complications of diabetes 6 10.6
37 microvascular complications of diabetes 2 10.6
38 primary angiitis of the central nervous system 10.6
39 microvascular complications of diabetes 5 10.6
40 brown-sequard syndrome 10.6
41 microvascular complications of diabetes 4 10.6
42 blue toe syndrome 10.6
43 erythermalgia, primary 10.6
44 microvascular complications of diabetes 3 10.6
45 hypertrophic olivary degeneration 10.6
46 ischemic optic neuropathy 10.6
47 arteritic anterior ischemic optic neuropathy 10.6
48 exudative vitreoretinopathy 3 10.6
49 exudative vitreoretinopathy 4 10.6
50 cerebral amyloid angiopathy, dutch, italian, iowa, flemish, arctic variants 10.6

Graphical network of the top 20 diseases related to Ischemia:



Diseases related to Ischemia

Symptoms & Phenotypes for Ischemia

UMLS symptoms related to Ischemia:


anoxemia, polydipsia, muscle weakness, angina pectoris

GenomeRNAi Phenotypes related to Ischemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.78 HIF1A HMOX1 MAP3K5 MPO NOS2 PRKAA2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.78 HMOX1 MAP3K5 MPO NOS2 PRKAA2 CASP3

MGI Mouse Phenotypes related to Ischemia:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.43 CDK5 EGR1 HIF1A HMOX1 HSPA4 HYOU1
2 cardiovascular system MP:0005385 10.42 CXCL12 EDN1 EGR1 HIF1A HMOX1 KCNJ11
3 homeostasis/metabolism MP:0005376 10.41 EDN1 EGR1 HIF1A HMOX1 HYOU1 KCNJ11
4 cellular MP:0005384 10.35 CASP3 CAV1 CXCL12 EGR1 HIF1A HMOX1
5 endocrine/exocrine gland MP:0005379 10.29 CASP3 CAV1 EDN1 EGR1 HIF1A HMOX1
6 hematopoietic system MP:0005397 10.27 ADORA3 CASP3 CAV1 CXCL12 EGR1 HIF1A
7 mortality/aging MP:0010768 10.27 ADORA1 CASP3 CAV1 CDK5 HMOX1 HSPA4
8 immune system MP:0005387 10.2 HIF1A HMOX1 MPO NOS2 NOS3 VEGFA
9 integument MP:0010771 10.13 KCNJ11 NOS2 VEGFA ADORA1 ADORA3 CASP3
10 nervous system MP:0003631 10.13 ADORA1 CASP3 CAV1 CDK5 CXCL12 EDN1
11 muscle MP:0005369 10.1 CASP3 CAV1 CXCL12 EDN1 HIF1A HMOX1
12 digestive/alimentary MP:0005381 10.07 CASP3 CAV1 EDN1 HIF1A NOS2 NOS3
13 liver/biliary system MP:0005370 10.01 CAV1 CXCL12 EGR1 HIF1A HMOX1 NOS2
14 renal/urinary system MP:0005367 9.9 ADORA1 ADORA3 CASP3 CAV1 EDN1 HIF1A
15 reproductive system MP:0005389 9.61 CASP3 CAV1 CXCL12 EGR1 HMOX1 HSPA4
16 respiratory system MP:0005388 9.36 CAV1 CDK5 EGR1 HIF1A HMOX1 NOS2

Drugs & Therapeutics for Ischemia

Drugs for Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1134)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Colchicine Approved Phase 4,Phase 2,Phase 3 64-86-8 6167 2833
2
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
3
Varenicline Approved, Investigational Phase 4,Phase 3 249296-44-4 5310966
4
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
5
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
6
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Phase 1 274693-27-5 9871419
7
Ezetimibe Approved Phase 4,Phase 3 163222-33-1 150311
8
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 55142-85-3 5472
9
Citalopram Approved Phase 4,Phase 1,Phase 2 59729-33-8 2771
10
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 73590-58-6 4594
11
Pantoprazole Approved Phase 4,Phase 3,Phase 2,Phase 1 102625-70-7 4679
12
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-78-2 2244
13
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
14 Trapidil Approved Phase 4 15421-84-8
15
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
16
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
17
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
18
Zolpidem Approved Phase 4 82626-48-0 5732
19
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
20
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
21
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 616-91-1 12035
22
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1 2216-51-5 16666
23
Esmolol Approved Phase 4,Phase 3,Phase 1,Phase 2 103598-03-4, 81147-92-4 59768
24
Nicardipine Approved Phase 4,Phase 3 55985-32-5 4474
25
Spironolactone Approved Phase 4,Phase 3,Phase 2 1952-01-7, 52-01-7 5833
26
Metformin Approved Phase 4 657-24-9 14219 4091
27
Valsartan Approved, Investigational Phase 4,Phase 2 137862-53-4 60846
28
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
29
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 2 72956-09-3 2585
30
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 28523-86-6 5206
31
Capsaicin Approved Phase 4,Phase 3,Phase 1,Phase 2 404-86-4 1548943
32
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6 772 46507594
33 Nadroparin Approved Phase 4 9041-08-1
34
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
35
Nimodipine Approved Phase 4,Phase 2 66085-59-4 4497
36
Atenolol Approved Phase 4,Phase 3 29122-68-7 2249
37
Clonidine Approved Phase 4,Phase 3,Phase 1,Phase 2 4205-90-7 2803
38
Ranolazine Approved, Investigational Phase 4,Phase 3,Phase 2 142387-99-3, 95635-55-5 56959
39
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
40
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55-56-1 9552079 2713
41
Abciximab Approved Phase 4,Phase 3,Phase 2 143653-53-6
42
Bivalirudin Approved, Investigational Phase 4,Phase 3 128270-60-0 16129704
43
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
44
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
45
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
46
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 124-94-7 31307
47
Adenosine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 58-61-7 60961
48
Nicorandil Approved Phase 4 65141-46-0 47528
49
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
50
Acarbose Approved, Investigational Phase 4 56180-94-0 441184

Interventional clinical trials:

(show top 50) (show all 6343)
id Name Status NCT ID Phase
1 Colchicine for Acute Coronary Syndromes Unknown status NCT01906749 Phase 4
2 Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome Unknown status NCT00815100 Phase 4
3 Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome Unknown status NCT01951001 Phase 4
4 Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome Unknown status NCT01170338 Phase 4
5 LDL-C Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day to10 mg/Day in Chinese ACS(Acute Coronary Syndrome) Patients Unknown status NCT02077257 Phase 4
6 Telmisartan Versus Ramipril After Acute Coronary Syndrome Unknown status NCT00702936 Phase 4
7 Intensive Lipid Lowering Treatment in Non-ST-elevation Acute Coronary Syndrome (NSTE-ACS) Patients Unknown status NCT01040936 Phase 4
8 Paradigm Shift in the Treatment of Patients With ACS Unknown status NCT02041650 Phase 4
9 Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome Unknown status NCT02341729 Phase 4
10 The Effects of Ezetimibe on Coronary Plaque Volume in Patients With Acute Coronary Syndrome Unknown status NCT01068093 Phase 4
11 Clopidogrel Reloading in Patients With NSTEACS Undergoing Percutaneous Coronary Intervention on Chronic Clopidogrel Therapy Unknown status NCT01572129 Phase 4
12 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4
13 "Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" -Trial dOPPLER- Unknown status NCT02028234 Phase 4
14 Acute Rosuvastatin for Preventing Myocardial Damage in Patients With ACS Unknown status NCT01245803 Phase 4
15 Efficacy of Ticagrelor vs Clopidogrel in High-risk NSTE-ACS Patients Undergoing Early PCI Unknown status NCT02201667 Phase 4
16 Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients Unknown status NCT02459288 Phase 4
17 Optical Coherence Tomography (OCT) Evaluation of Re-endothelization: A Comparison of the Intrepide™ Stent Versus Taxus™ Unknown status NCT00914420 Phase 4
18 Exploring Efficacy of Intensive Rosuvastatin Treatment Peri-PCI in Chinese Patients With Non ST-segment Elevated Acute Coronary Syndrome(NSTE-ACS) Unknown status NCT02284503 Phase 4
19 Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome Unknown status NCT01372839 Phase 4
20 Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor . Unknown status NCT02032303 Phase 4
21 Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel Unknown status NCT02032290 Phase 4
22 Impact of Ticagrelor on the Endothelial Healing Following Drug-eluting Stent Implantation in the Patients With Acute Coronary Syndrome Unknown status NCT02037412 Phase 4
23 Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Unknown status NCT01418794 Phase 4
24 The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel Unknown status NCT01365221 Phase 4
25 Effects of Zolpidem CR® in Sleep and Heart Recovery in Cardiac Intensive Care Unit Patients Unknown status NCT01920334 Phase 4
26 Vitamin D and Inflammatory Cytokine Levels After Acute Myocardial Infraction (MI) Unknown status NCT01115842 Phase 4
27 Fenoldopam for Prevention of Acute Kidney Injury Unknown status NCT01690832 Phase 4
28 Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN) Unknown status NCT01735227 Phase 4
29 Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy Unknown status NCT00939913 Phase 4
30 CT Coronary Angiogram Versus Traditional Care in Emergency Department Assessment of Potential ACS Unknown status NCT00933400 Phase 4
31 Hormones Inflammation and Thrombosis Unknown status NCT01875185 Phase 4
32 Comparative Phase IV Study: Efficacy And Safety of TiTAN2 Versus COBALT-CHROME Stents- EVIDENCEII Unknown status NCT01918150 Phase 4
33 Customized Choice of Oral P2Y12 Receptor Blocker Unknown status NCT01477775 Phase 4
34 Aspirin Resistance and Prognosis of Patients With Critical Limb Ischaemia Unknown status NCT01104441 Phase 4
35 Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis Unknown status NCT02048085 Phase 4
36 Comparison of Intravenous Injection of Calcium Antagonist and Beta-blockade on Endothelial Shear Stress of Coronary Artery Unknown status NCT01171911 Phase 4
37 Diagnosis and Treatment of ACS in the ED: The Impact of Rapid Bedside cTnI Testing on Outcomes Unknown status NCT00222352 Phase 4
38 Potential Impact of Cigarette Smoking on Platelet Reactivity in Patients on Dual Antiplatelet Therapy With P2Y12 Inhibitors Unknown status NCT02026713 Phase 4
39 Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD Unknown status NCT02008786 Phase 4
40 Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI Unknown status NCT02012140 Phase 4
41 Randomized Trial of Creatine-kinase Leak After Rosuvastatin At the Time of Percutaneous Coronary Intervention Unknown status NCT01968577 Phase 4
42 Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery Unknown status NCT01201070 Phase 4
43 Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment Unknown status NCT01761786 Phase 4
44 Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure Unknown status NCT00527059 Phase 4
45 The Effects of Continuous Positive Airway Pressure on Overlap Syndrome Unknown status NCT00914264 Phase 4
46 FRC Guided Therapy in Acute Respiratory Failure Unknown status NCT01280019 Phase 4
47 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4
48 A Morbidity-Mortality and Remodeling Study With Valsartan Unknown status NCT00133328 Phase 4
49 Comparative Study of Non-Invasive Mask Ventilation vs Cuirass Ventilation in Patients With Acute Respiratory Failure. Unknown status NCT00331656 Phase 4
50 Randomized Study of Pregabalin for Pain Reduction in Patients With Rest Pain and Lower Limb Ischemia Unknown status NCT00403780 Phase 4

Search NIH Clinical Center for Ischemia

Cochrane evidence based reviews: ischemia

Genetic Tests for Ischemia

Anatomical Context for Ischemia

MalaCards organs/tissues related to Ischemia:

39
Brain, Spinal Cord, Heart, Endothelial, Liver, Kidney, Bone

Publications for Ischemia

Articles related to Ischemia:

(show top 50) (show all 6169)
id Title Authors Year
1
Long non-coding RNA MALAT1 functions as a mediator in cardioprotective effects of fentanyl in myocardial ischemia-reperfusion injury. ( 27862640 )
2017
2
Cell therapy in critical limb ischemia: A comprehensive analysis of two cell therapy products. ( 27914820 )
2017
3
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY SHOWS INNER CHOROIDAL ISCHEMIA IN ACUTE POSTERIOR MULTIFOCAL PLACOID PIGMENT EPITHELIOPATHY. ( 27759710 )
2017
4
Postconditioning-induced neuroprotection, mechanisms and applications in cerebral ischemia. ( 28087295 )
2017
5
Myeloid differentiation protein 2-dependent mechanisms in retinal ischemia-reperfusion injury. ( 28063877 )
2017
6
Inhibition of DPP-4 Activity and Neuronal Atrophy with Genistein Attenuates Neurological Deficits Induced by Transient Global Cerebral Ischemia and Reperfusion in Streptozotocin-Induced Diabetic Mice. ( 28091829 )
2017
7
Vascular calcification abrogates the nicorandil mediated cardio-protection in ischemia reperfusion injury of rat heart. ( 28087358 )
2017
8
Britanin Ameliorates Cerebral Ischemia-Reperfusion Injury by Inducing the Nrf2 Protective Pathway. ( 28186440 )
2017
9
Electrophysiological alterations in diaphragm muscle caused by abdominal ischemia-reperfusion. ( 28087340 )
2017
10
Neutrophil-to-lymphocyte ratio is effective prognostic indicator for post-amputation patients with critical limb ischemia. ( 28042626 )
2017
11
Long-Term Outcomes of Successful Endovascular Therapy Via the Retrograde Approach for Below-the-Knee Chronic Total Occlusion in Patients With Critical Limb Ischemia After a Failed Antegrade Approach. ( 28045669 )
2017
12
Assessment of ischemia in acute central retinal vein occlusion from inner retinal reflectivity on spectral domain optical coherence tomography. ( 28053503 )
2017
13
Intraarterial route increases the risk of cerebral lesions after mesenchymal cell administration in animal model of ischemia. ( 28091591 )
2017
14
The use of therapeutic magnesium for neuroprotection during global cerebral ischemia associated with cardiac arrest and cardiac surgery in adults: a systematic review. ( 28085730 )
2017
15
Diagnostic and Prognostic Relevance of Magnetic Resonance Imaging and Electrophysiological Findings in Acute Spinal Ischemia. ( 28089563 )
2017
16
Curcumin reverses neurochemical, histological and immuno-histochemical alterations in the model of global brain ischemia. ( 28053883 )
2017
17
Acute mesenteric ischemia and hepatic infarction after treatment of ectopic Cushing's syndrome. ( 28480039 )
2017
18
Inorganic Nitrite modulates miRNA Signatures in Acute Myocardial in vivo Ischemia/Reperfusion. ( 28090786 )
2017
19
Overexpression of Gremlin1 in Mesenchymal Stem Cells Improves Hindlimb Ischemia in Mice by Enhancing Cell Survival. ( 27579673 )
2017
20
PEGylated insulin-like growth factor-I affords protection and facilitates recovery of lost functions post-focal ischemia. ( 28325900 )
2017
21
Phosphodiesterase type 5 inhibition may reduce diastolic function in women with ischemia but no obstructive coronary artery disease. ( 28528579 )
2017
22
Increase in urinary markers during the acute phase reflects the degree of chronic tubulointerstitial injury after ischemia-reperfusion renal injury. ( 27028054 )
2017
23
Profiling and identification of new proteins involved in brain ischemia using MALDI-imaging-mass-spectrometry. ( 27888142 )
2017
24
Neuroprotective effects of Kukoamine A against cerebral ischemia via antioxidant and inactivation of apoptosis pathway. ( 28088348 )
2017
25
Improvement of Subjective Well-Being by Ranolazine in Patients with Chronic Angina and Known Myocardial Ischemia (IMWELL Study). ( 28044265 )
2017
26
Nuclear Factor (Erythroid-Derived 2)-Like 2 and Thioredoxin-1 in Atherosclerosis and Ischemia/Reperfusion Injury in the Heart. ( 27923281 )
2017
27
Polyarteritis nodosa presenting as peripheral vascular disease and acute limb ischemia. ( 27853042 )
2017
28
Quality of life as predictor for the development of cardiac ischemia in high-risk asymptomatic diabetic patients. ( 28091969 )
2017
29
Neutralizing anti-interleukin-1I^ antibodies reduce ischemia-related interleukin-1I^ transport across the blood-brain barrier in fetal sheep. ( 28089577 )
2017
30
Piperine modulates isoproterenol induced myocardial ischemia through antioxidant and anti-dyslipidemic effect in male Wistar rats. ( 28088738 )
2017
31
Inframalleolar Interventions in Critical Limb Ischemia: Trailblazing the Path Toward the Final Frontier? ( 28057290 )
2017
32
Effect of Physical and Social Components of Enriched Environment on Astrocytes Proliferation in Rats After Cerebral Ischemia/Reperfusion Injury. ( 28083848 )
2017
33
Electroacupuncture pretreatment attenuates spinal cord ischemia-reperfusion injury via inhibition of high-mobility group box 1 production in a LXA4 receptor-dependent manner. ( 28089662 )
2017
34
Fetal Alcohol Exposure Alters Blood Flow and Neurological Responses to Transient Cerebral Ischemia in Adult Mice. ( 27987329 )
2017
35
Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy - successful treatment with lipoprotein apheresis. ( 28160245 )
2017
36
Glutamate dehydrogenase as a neuroprotective target against brain ischemia and reperfusion. ( 27845178 )
2017
37
Salvianolic Acids for Injection (SAFI) Suppresses Inflammatory Responses in Activated Microglia to Attenuate Brain Damage in Focal Cerebral Ischemia. ( 28087473 )
2017
38
Takayasu arteritis (TA) first presenting with intestinal ischemia: a case report and review of gastrointestinal tract involvement (ischemic and non-ischemic) associated with TA. ( 27832292 )
2017
39
Effects of Deltorphin II and Its Retroenantio Analog on Cardiac Tolerance to Ischemia and Reperfusion. ( 28091919 )
2017
40
Anticoagulants in ischemia-guided management of non-ST-elevation acute coronary syndromes. ( 28089498 )
2017
41
A 37-year-old man with primary antiphospholipid syndrome presenting with respiratory distress and worsening toe ischemia. ( 27992694 )
2016
42
Murine Model of Intestinal Ischemia-reperfusion Injury. ( 27213580 )
2016
43
Astragaloside IV attenuates cognitive impairments induced by transient cerebral ischemia and reperfusion in mice via anti-inflammatory mechanisms. ( 28011393 )
2016
44
Cost-effectiveness analysis of initial treatment strategies for nonembolic acute limb ischemia using real word data. ( 27575302 )
2016
45
Polarizing the immune system towards neuroprotection in brain ischemia. ( 26981089 )
2016
46
Involvement of microRNA-181a and Bim in a rat model of retinal ischemia-reperfusion injury. ( 26949607 )
2016
47
Porcine model for observing changes due to ischemia/reperfusion injury secondary to intra-abdominal endovascular balloon occlusion. ( 27216599 )
2016
48
Quality of life assessment as an outcomes measure in critical limb ischemia. ( 27876523 )
2016
49
EEG power as a biomarker to predict the outcome after cardiac arrest and cardiopulmonary resuscitation induced global ischemia. ( 27640888 )
2016
50
Discharge Destination after Elective Femoropopliteal Bypass in Patients without Critical Ischemia. ( 27215729 )
2016

Variations for Ischemia

Copy number variations for Ischemia from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 72977 12 89000000 92600000 Copy number GALNT4 Acute coronary syndrome

Expression for Ischemia

Search GEO for disease gene expression data for Ischemia.

Pathways for Ischemia

Pathways related to Ischemia according to GeneCards Suite gene sharing:

(show all 32)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.22 CASP3 CAV1 CXCL12 HSPA4 MAP3K5 NOS3
2
Show member pathways
12.81 CASP3 CAV1 CTSL CXCL12 HSPA4 VEGFA
3
Show member pathways
12.73 ADORA3 CASP3 CAV1 CXCL12 EDN1 EGR1
4
Show member pathways
12.69 CASP3 CDK5 EGR1 HIF1A MAP3K5 NOS3
5 12.61 CASP3 CXCL12 HIF1A NOS2 VEGFA
7 12.22 CASP3 CAV1 CTSL HIF1A VEGFA
8
Show member pathways
12.21 CASP3 EGR1 HIF1A MAP3K5 VEGFA
9 12.12 CASP3 EGR1 HIF1A VEGFA
10 12.06 CASP3 CDK5 EGR1 PRKAA2
11 12.04 EGR1 NOS2 NOS3 PRKAA2
12 11.96 ADORA1 ADORA3 MAP3K5 NOS3
13 11.93 HIF1A HMOX1 NOS2 VEGFA
14 11.81 CASP3 MAP3K5 NOS3 PRKAA2
15 11.79 CTSL CXCL12 VEGFA
16
Show member pathways
11.79 CAV1 HIF1A NOS3 VEGFA
17 11.76 HIF1A HMOX1 NOS3
18
Show member pathways
11.74 CASP3 CXCL12 MAP3K5
19 11.72 CASP3 EDN1 EGR1 NOS3 VEGFA
20 11.63 EDN1 HIF1A HMOX1 NOS2 NOS3 VEGFA
21 11.62 CASP3 HIF1A NOS2 NOS3
22
Show member pathways
11.57 HSPA4 NOS2 NOS3
23 11.51 EDN1 HIF1A NOS3 VEGFA
24 11.44 CASP3 HIF1A NOS2 VEGFA
25 11.37 CAV1 CTSL EDN1 HMOX1 MAP3K5 NOS3
26 11.27 EDN1 HIF1A NOS2 VEGFA
27 11.25 CXCL12 EDN1 HIF1A HMOX1 NOS2 VEGFA
28 11.1 HIF1A NOS3 VEGFA
29
Show member pathways
11.03 EDN1 EGR1 HIF1A VEGFA
30 10.76 NOS2 NOS3
31 10.59 HIF1A VEGFA
32 10.53 NOS2 NOS3

GO Terms for Ischemia

Cellular components related to Ischemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 caveola GO:0005901 8.8 CAV1 HMOX1 NOS3

Biological processes related to Ischemia according to GeneCards Suite gene sharing:

(show all 40)
id Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.92 CASP3 EDN1 MPO NOS2
2 positive regulation of angiogenesis GO:0045766 9.84 HIF1A HMOX1 NOS3 VEGFA
3 response to wounding GO:0009611 9.83 ADORA3 CASP3 CDK5
4 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.83 EGR1 HIF1A VEGFA
5 regulation of blood pressure GO:0008217 9.82 EDN1 HMOX1 NOS3
6 positive regulation of endothelial cell proliferation GO:0001938 9.82 CXCL12 HIF1A VEGFA
7 regulation of macroautophagy GO:0016241 9.81 CASP3 CDK5 PRKAA2
8 cellular response to drug GO:0035690 9.8 EDN1 NOS2 PRKAA2
9 negative regulation of apoptotic process GO:0043066 9.8 ADORA1 CASP3 HIF1A HYOU1 MPO PRKAA2
10 angiogenesis GO:0001525 9.77 CAV1 HIF1A HMOX1 NOS3 VEGFA
11 lactation GO:0007595 9.75 CAV1 HIF1A VEGFA
12 response to nicotine GO:0035094 9.74 CASP3 EDN1 HMOX1
13 negative regulation of blood pressure GO:0045776 9.7 ADORA1 NOS2 NOS3
14 positive regulation of neuron death GO:1901216 9.69 CDK5 EGR1 MAP3K5
15 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.68 HIF1A VEGFA
16 positive regulation of glycolytic process GO:0045821 9.68 HIF1A PRKAA2
17 removal of superoxide radicals GO:0019430 9.68 MPO NOS3
18 induction of positive chemotaxis